Cellular effects of combined adriamycin and x‐irradiation in human tumor cells

Byfield, John E.; Lynch, Michael J.; Kulhanian, Fimi; Chan, Paul Y. M.

doi:10.1002/ijc.2910190209

Cited by 52 publications

(19 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The curves in Fig. 1 are similar to those for ADR (Byfield et al, 1977; 1977). In view of the toxicity of m-AMSA, when cells were irradiated in combination with the drug the surviving fractions were calculated by normalizing the observed survivors to the number of survivors in unirradiated cultures that had been exposed to the drug for a similar length of time.…”

Section: Resultssupporting

confidence: 66%

See 1 more Smart Citation

Enhanced killing of mammalian cells by radiation combined with m-AMSA

Roberts¹,

Millar²

1980

Br J Cancer

View full text Add to dashboard Cite

Summary.-m-AMSA is an intercalating agent at present on Phase II trial as a chemotherapeutic drug. A 30min exposure of Chinese hamster (Line V79-753B) cells to submicromolar concentrations of m-AMSA killed 50%O of the cells. The survivors had an enhanced sensitivity to radiation-induced cell killing. Depending upon the conditions, m-AMSA enhanced the radiation effect by either a decrease in the survival-curve shoulder or by an increase in slope. m-AMSA may act partly by suppressing the accumulation of sublethal damage but, if so, recovery from damage as measured in split-dose experiments with cells pretreated with the drug is not affected. m-AMSA increased radiation lethality throughout the cell cycle, but a contribution to its radiation effect from selective toxicity to cells in a radioresistant phase of the cell cycle cannot be excluded. Radiation and the drug interacted to give increased cell killing, even when the exposures to each agent were separated in time.It is concluded that m-ASMA may behave like actinomycin D and adriamycin, and enhance clinical radiation responses. In vivo testing to determine the effect of m-AMSA on the therapeutic index is recommended. AMONG THE NEW CYTOTOXIC AGENTSthat therapists hope will extend the range of cancer chemotherapeutic drugs are the 9-anilinoacridines developed by Cain and his co-workers (Denny et al., 1978, and references therein). Reversibility of myelosuppression and limited other side effects are attractive features of m-AMSA (4'-[9 -acridinylamino] -methanesulphon -manisidide) the derivative on which attention has been focused initially.

show abstract

Section: Resultssupporting

confidence: 66%

“…The ability of the experimental conditions to determine whether changes in n or Do describe the enhancement of radiation effects is not unique to m-AMSA. Other intercalating agents exhibiting similar behaviour are AMD (Elkind & Whitmore, 1967), ADR (compare Belli & Piro, 1977, with Byfield et al, 1977 and quinacrine (Saladino & Ben-Hur, 1978).…”

Section: Resultsmentioning

confidence: 98%

Enhanced killing of mammalian cells by radiation combined with m-AMSA

Roberts¹,

Millar²

1980

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Radiation may also interact with the chemotherapeutic drug while the drug stays in the tumors after TACE. Adriamycin, injected at the time of TACE, is well known to augment the antitumor efficacy of radiation 58. This drug, when mixed with Lipiodol, has been reported to maintain relatively high concentration in tumors as long as 27 days and decrease to a trace level after 47 days 59,60.…”

Section: Practice Of Radiotherapy For Hepatocellular Carcinomamentioning

confidence: 99%

Challenge and Hope in Radiotherapy of Hepatocellular Carcinoma

Seong

2009

Yonsei Med J

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most critical global health issues. With frequent association of viral liver disease, HCC is highly complex, harboring both cancer and chronic liver disease. The tumor stage and underlying liver function are both major determinants of the treatment selection as well as prognosis in HCC patients, thus allowing no more than a 20% chance for potentially curative therapies. Radiotherapy technology has been evolved remarkably during the past decade, and radiation can be precisely delivered, thereby permitting higher doses to the tumour and reduced doses to surrounding normal tissues. There has been increasing interest in the merits of radiotherapy in HCC over the past few years, as indicated by a Pub Med search. Radiotherapy has been used as the definitive therapy with curative intent in early stage tumours. It has been used also in combination with TACE for intermediate stage tumours. In locally advanced tumours, radiotherapy has been combined with systemic agents. Despite its efficacy, radiotherapy has not yet been incorporated into the standard management guidelines of HCC. The lack of high evidence level data, especially randomized controlled trials, has posed an obstacle in including radiotherapy into the routine treatment schema of HCC. Therefore, well-designed prospective studies are strongly recommended using developing technology for radiotherapy alone or combination therapies. Also, many issues such as the optimal dose-fractionation, intra- or extrahepatic metastasis after radiotherapy, and radiation-induced hepatic dysfunction remain to be solved. In this review, current status of radiotherapy for HCC will be discussed with regard to technical consideration and combination strategy. The limitation and future perspectives will also be discussed.

show abstract

“…The combination of doxorubicin and radiation in mammalian tumour cells is synergistic when a low dose of this cytostatic agent (50.15 mg kg 71 ) is used (Byfield et al, 1977). The mechanism responsible for the radiosensitising effect of doxorubicin is a subject of speculation (Rosenthal and Rotman, 1991).…”

mentioning

confidence: 99%

Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery

et al. 2002

View full text Add to dashboard Cite

Patients with anaplastic thyroid carcinoma can rarely be cured, but every effort should be made to prevent death due to suffocation. Between 1984 and 1999, 55 consecutive patients with anaplastic thyroid carcinoma were prospectively treated according to a combined regimen consisting of hyperfractionated radiotherapy, doxorubicin, and when feasible surgery. Radiotherapy was carried out for 5 days a week. The daily fraction until 1988 was 1.0 Gy×2 (A) and 1989–92 1.3 Gy×2 (B) . Thereafter 1.6 Gy×2 (C) was administered. Radiotherapy was administered to a total target dose of 46 Gy; of which 30 Gy was administered preoperatively in the first two protocols (A and B), while the whole dose was given preoperatively in the third protocol (C). The therapy was otherwise identical. Twenty mg doxorubicin was administered intravenously weekly. Surgery was possible in 40 patients. No patient failed to complete the protocol due to toxicity. In only 13 cases (24%) was death attributed to local failure. Five patients (9%) ‘had a survival’ exceeding 2 years. No signs of local recurrence were seen in 33 patients (60%); 5 out of 16 patients in Protocol A, 11 out of 17 patients in Protocol B, 17 out of 22 patients in Protocol C ( P =0.017). In the 40 patients undergoing additional surgery, no signs of local recurrence were seen in 5 out of 9 patients, 11 out of 14 patients and 17 out of 17 patients, respectively ( P =0.005). British Journal of Cancer (2002) 86 , 1848–1853. doi: 10.1038/sj.bjc.6600361 www.bjcancer.com © 2002 Cancer Research UK

show abstract

Cellular effects of combined adriamycin and x‐irradiation in human tumor cells

Cited by 52 publications

References 21 publications

Enhanced killing of mammalian cells by radiation combined with m-AMSA

Enhanced killing of mammalian cells by radiation combined with m-AMSA

Challenge and Hope in Radiotherapy of Hepatocellular Carcinoma

Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery

Contact Info

Product

Resources

About